Across TCGA pan-cancer cohorts, ACSM2A mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ACSM2A data layer compared with 18 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ACSM2A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ACSM2A expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC are the cancer types where ACSM2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.962	0.738	.009	4	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

Exploration

Same gene, other analysis: ACSM2A tumor-vs-normal RNA expression · all ACSM2A data types